[
    [
        {
            "time": "2018-01-02",
            "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV",
            "features": {
                "keywords": [
                    "class action",
                    "shareholder losses",
                    "AbbVie"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "AbbVie Permits US Sale of Sandoz's Humira Biosimilar",
            "features": {
                "keywords": [
                    "Humira",
                    "biosimilar",
                    "US sale"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Permits US Sale of Sandoz's Humira Biosimilar",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY",
            "features": {
                "keywords": [
                    "class actions",
                    "shareholders",
                    "ABBV"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal",
            "features": {
                "keywords": [
                    "Humira",
                    "biosimilar agreement",
                    "cancer deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "AbbVie Losses Alert: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV",
            "features": {
                "keywords": [
                    "class action lawsuit",
                    "investor deadline",
                    "AbbVie"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Losses Alert: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "AbbVie Settles With Novartis to Delay Humira Biosimilar in US",
            "features": {
                "keywords": [
                    "settlement",
                    "Humira",
                    "biosimilar delay"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Settles With Novartis to Delay Humira Biosimilar in US",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Bristol-Myers Inks Deal and Invests $12 Million in Compugen",
            "features": {
                "keywords": [
                    "deal",
                    "investment",
                    "Compugen"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Bristol-Myers Inks Deal and Invests $12 Million in Compugen",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal",
            "features": {
                "keywords": [
                    "Humira",
                    "biosimilar agreement",
                    "cancer deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018",
            "features": {
                "keywords": [
                    "class action",
                    "lead plaintiff deadline",
                    "AbbVie"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "3 Big Pharma Stocks Racing Along the Road to China",
            "features": {
                "keywords": [
                    "big pharma",
                    "China market"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Big Pharma Stocks Racing Along the Road to China",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "Abbvie settles Humira patent disputes with Novartis unit",
            "features": {
                "keywords": [
                    "patent disputes",
                    "settlement",
                    "Novartis"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbvie settles Humira patent disputes with Novartis unit",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",
            "features": {
                "keywords": [
                    "FDA rejection",
                    "private company",
                    "cancer vaccine discontinuation"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]